THE SAFETY AND EFFICACY OF SOLIFENACIN AS COMPARED TO MIRABEGRON IN OVERACTIVE BLADDER SYNDROME PATIENTS IN THE ADULT POPULATION OF DERA ISMAIL KHAN

M  SEERWAN; M ADNAN; H SHAFI; N JAVED; M  ILYAS; M HUSSAIN

doi:10.54112/bcsrj.v2023i1.239

Authors

M SEERWAN Department of Urology, Gomal Medical College D.I Khan, Pakistan
M ADNAN Department of Urology, Bakhtawar Amin Medical & Dental College Multan, Pakistan
H SHAFI Department of Urology, Sheikh Zayed Hospital Lahore, Pakistan
N JAVED Department of Urology, The Children’s Hospital & the University of Child Health Sciences Lahore, Pakistan
M ILYAS Department of Urology, Gomal Medical College D.I Khan, Pakistan
M HUSSAIN Department of Urology, Sharif Medical & Dental College Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.239

Keywords:

Overactive bladder syndrome, Solifenacin;., Mirabegron, Adult population

Abstract

An overactive bladder syndrome is a group of symptoms, i.e., frequency, urgency, nocturia, and sometimes accompanied by urge incontinence. The recent pharmacological options are some drugs, mainly used anti-muscarinic. However, anti-muscarinic drugs have different adverse effects, i.e., constipation and dry mouth. In 2011, a β3 receptor agonist, mirabegron, was studied to treat overactive bladder syndrome. This non-randomized trial was conducted in the Department of Urology, Gomal medical college, D.I. Khan, KPK Pakistan. The study was done from June 2018 to January 2022. We divided 4220 patients into two equal groups. Group a used solifenacin 5 mg for 6 weeks, while group B used mirabegron 50 mg for the same duration. We assessed safety and efficacy after 6 weeks. Most of the adverse effects were mild to moderate severity. Dry mouth occurred in 125 patients out of 2110 (5.92%) in group A and 66 out of 2110 (3.12%) in group B. p-value = 0.0001. Constipation occurred in 53 (2.51%) patients in group A and 46 (2.18%) patients in group B. p-value=0.5417. The improvement in overactive bladder symptoms score (OBSS) occurred in 1443 out of 2110 (68.38%) patients in group A and 1409 out of 2110 (66.77%) patients in group B. p-value=0.2778. Based on the results, it can be concluded that Mirabegron has fewer adverse effects than solifenacin, while both drugs are approximately similar in efficacy.

Downloads

Download data is not yet available.

References

Ahmad, W., Rehman, S., Aamir, M., and Waheed, D. (2022). PATENCY RATE OF BRACHIOCEPHALIC VS RADIOCEPHALIC AVF IN CHRONIC KIDNEY DISEASE PATIENTS IN POPULATION OF DI KHAN DIVISION, PAKISTAN. Gomal Journal of Medical Sciences 20.

Batista, J. E., Kölbl, H., Herschorn, S., Rechberger, T., Cambronero, J., Halaska, M., Coppell, A., Kaper, M., Huang, M., and Siddiqui, E. (2015). The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Therapeutic advances in urology 7, 167-179.

Chapple, C. R., Cardozo, L., Nitti, V. W., Siddiqui, E., and Michel, M. C. (2014). Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourology and urodynamics 33, 17-30.

Condino, A. M., and Calvi, P. (2015). Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [3H]-acetylcholine release experiments in the isolated detrusor. European Journal of Pharmacology 758, 115-122.

Coyne, K. S., Sexton, C. C., Irwin, D. E., Kopp, Z. S., Kelleher, C. J., and Milsom, I. (2008). The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study. BJU international 101, 1388-1395.

FUJIMURA, T., TAMURA, K., TSUTSUMI, T., YAMAMOTO, T., NAKAMURA, K., KOIBUCHI, Y., KOBAYASHI, M., and YAMAGUCHI, O. (1999). Expression and possible functional role of the beta 3-adrenoceptor in human and rat detrusor muscle. The Journal of urology 161, 680-685.

Haylen, B. T., De Ridder, D., Freeman, R. M., Swift, S. E., Berghmans, B., Lee, J., Monga, A., Petri, E., Rizk, D. E., and Sand, P. K. (2010). An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourology and Urodynamics: Official Journal of the International Continence Society 29, 4-20.

Homma, Y., Yamaguchi, O., Hayashi, K., and Committee, M. o. t. N. B. S. (2005). An epidemiological survey of overactive bladder symptoms in Japan. BJU international 96, 1314-1318.

Homma, Y., Yoshida, M., Seki, N., Yokoyama, O., Kakizaki, H., Gotoh, M., Yamanishi, T., Yamaguchi, O., Takeda, M., and Nishizawa, O. (2006). Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 68, 318-323.

Inoue, M., and Yokoyama, T. (2019). Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study. Acta Medica Okayama 73, 387-392.

Kreydin, E. I., Gomes, C. M., and Cruz, F. (2021). Current pharmacotherapy of overactive bladder. International braz j urol 47, 1091-1107.

Maman, K., Aballea, S., Nazir, J., Desroziers, K., Neine, M.-E., Siddiqui, E., Odeyemi, I., and Hakimi, Z. (2014). Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. European urology 65, 755-765.

Nitti, V., Khullar, V., Van Kerrebroeck, P., Herschorn, S., Cambronero, J., Angulo, J., Blauwet, M., Dorrepaal, C., Siddiqui, E., and Martin, N. (2013). Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies. International journal of clinical practice 67, 619-632.

Pagano, M., Gauvreau, K., and Mattie, H. (2022). "Principles of biostatistics," CRC Press.

Rosa, G. M., Ferrero, S., Nitti, V. W., Wagg, A., Saleem, T., and Chapple, C. R. (2016). Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. European urology 69, 311-323.

Takeda, H., Matsuzawa, A., Igawa, Y., Yamazaki, Y., Kaidoh, K., Akahane, S., Kojima, M., Miyata, H., Akahane, M., and Nishizawa, O. (2003). Functional characterization of β-adrenoceptor subtypes in the canine and rat lower urinary tract. The Journal of urology 170, 654-658.

Takeda, M., Obara, K., Mizusawa, T., Tomita, Y., Arai, K., Tsutsui, T., Hatano, A., Takahashi, K., and Nomura, S. (1999). Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. Journal of Pharmacology and Experimental Therapeutics 288, 1367-1373.

Yamaguchi, O., Marui, E., Kakizaki, H., Homma, Y., Igawa, Y., Takeda, M., Nishizawa, O., Gotoh, M., Yoshida, M., and Yokoyama, O. (2014). Phase III, randomised, double‐blind, placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily, in J apanese patients with overactive bladder. BJU international 113, 951-960.

Yeowell, G., Smith, P., Nazir, J., Hakimi, Z., Siddiqui, E., and Fatoye, F. (2018). Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ open 8, e021889.

Zar, J. H. (1999). "Biostatistical analysis," Pearson Education India